Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biphasic insulin aspart 30 once daily versus insulin glargine once daily added to metformin and glimepiride in insulin-naive type 2 diabetes
2006-003288-29Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Biphasic insulin aspart 30 arm with Insulin glargine arm (2 arms). Primary endpoint: Glycaemic control measured by HbA1c after 26 weeks. Started Jan 2007; status: completed.
02
Drugs
biphasic insulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-003288-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003288-29.